BMS welcomes new Board member

Bristol-Myers Squibb’s Board of Directors has elected José Baselga, M.D., Ph.D., to the Board, effective March 1, 2018. Dr. Baselga will serve as a member of Science & Technology Committee of the Board of Directors.

Baselga, 58, is currently the Physician-in-Chief at Memorial Sloan Kettering Cancer Center, one of the world’s premier cancer institutions, where he is responsible for the management of patient care and plays an active role in efforts to enhance and expand programs in clinical and translational research.

“José is an internationally-recognized physician scientist in oncology with deep experience in teaching at leading academic institutions, pioneering research for targeted cancer therapies and treating patients, which he still continues today,” said Giovanni Caforio, M.D., chairman and chief executive officer, Bristol-Myers Squibb. “His close engagement with emerging science across biotech and shared focus on patients brings valuable contributions to helping us advance our strategy and pipeline of transformational medicines.”

“With over 30 years of experience at the bench and in the clinic, José brings a voice of innovation and practical, patient-centric solutions to the Board,” said Vicki L. Sato, Ph.D., lead independent director, Bristol-Myers Squibb. “His knowledge across cancer biology and drug development will bring tremendous value to Bristol-Myers Squibb, and we look forward to working together to advance new therapies for patients.”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.